These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 19632069

  • 1. Local control following permanent prostate brachytherapy: effect of high biologically effective dose on biopsy results and oncologic outcomes.
    Stone NN, Stock RG, Cesaretti JA, Unger P.
    Int J Radiat Oncol Biol Phys; 2010 Feb 01; 76(2):355-60. PubMed ID: 19632069
    [Abstract] [Full Text] [Related]

  • 2. Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score 7-10 prostate cancer treated with permanent prostate brachytherapy.
    Stone NN, Potters L, Davis BJ, Ciezki JP, Zelefsky MJ, Roach M, Shinohara K, Fearn PA, Kattan MW, Stock RG.
    Int J Radiat Oncol Biol Phys; 2009 Feb 01; 73(2):341-6. PubMed ID: 18597953
    [Abstract] [Full Text] [Related]

  • 3. Association of percent positive prostate biopsies and perineural invasion with biochemical outcome after external beam radiotherapy for localized prostate cancer.
    Wong WW, Schild SE, Vora SA, Halyard MY.
    Int J Radiat Oncol Biol Phys; 2004 Sep 01; 60(1):24-9. PubMed ID: 15337536
    [Abstract] [Full Text] [Related]

  • 4. Patterns of local failure following prostate brachytherapy.
    Stone NN, Stock RG, White I, Unger P.
    J Urol; 2007 May 01; 177(5):1759-63; duscussion 1763-4. PubMed ID: 17437808
    [Abstract] [Full Text] [Related]

  • 5. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
    Kupelian P, Kuban D, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A.
    Int J Radiat Oncol Biol Phys; 2005 Feb 01; 61(2):415-9. PubMed ID: 15667961
    [Abstract] [Full Text] [Related]

  • 6. Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy.
    Ho AY, Burri RJ, Cesaretti JA, Stone NN, Stock RG.
    Int J Radiat Oncol Biol Phys; 2009 Sep 01; 75(1):16-22. PubMed ID: 19289266
    [Abstract] [Full Text] [Related]

  • 7. Lack of benefit of pelvic radiation in prostate cancer patients with a high risk of positive pelvic lymph nodes treated with high-dose radiation.
    Vargas CE, Galalae R, Demanes J, Harsolia A, Meldolesi E, Nürnberg N, Schour L, Martinez A.
    Int J Radiat Oncol Biol Phys; 2005 Dec 01; 63(5):1474-82. PubMed ID: 15964706
    [Abstract] [Full Text] [Related]

  • 8. Biologically effective dose (BED) correlation with biochemical control after low-dose rate prostate brachytherapy for clinically low-risk prostate cancer.
    Miles EF, Nelson JW, Alkaissi AK, Das S, Clough RW, Broadwater G, Anscher MS, Chino JP, Oleson JR.
    Int J Radiat Oncol Biol Phys; 2010 May 01; 77(1):139-46. PubMed ID: 19836161
    [Abstract] [Full Text] [Related]

  • 9. Customized dose prescription for permanent prostate brachytherapy: insights from a multicenter analysis of dosimetry outcomes.
    Stone NN, Potters L, Davis BJ, Ciezki JP, Zelefsky MJ, Roach M, Fearn PA, Kattan MW, Stock RG.
    Int J Radiat Oncol Biol Phys; 2007 Dec 01; 69(5):1472-7. PubMed ID: 17689026
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Long-term prostate cancer control using palladium-103 brachytherapy and external beam radiotherapy in patients with a high likelihood of extracapsular cancer extension.
    Dattoli M, Wallner K, True L, Cash J, Sorace R.
    Urology; 2007 Feb 01; 69(2):334-7. PubMed ID: 17320673
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Changing the patterns of failure for high-risk prostate cancer patients by optimizing local control.
    Stock RG, Ho A, Cesaretti JA, Stone NN.
    Int J Radiat Oncol Biol Phys; 2006 Oct 01; 66(2):389-94. PubMed ID: 16965991
    [Abstract] [Full Text] [Related]

  • 15. Population-based study of biochemical and survival outcomes after permanent 125I brachytherapy for low- and intermediate-risk prostate cancer.
    Morris WJ, Keyes M, Palma D, Spadinger I, McKenzie MR, Agranovich A, Pickles T, Liu M, Kwan W, Wu J, Berthelet E, Pai H.
    Urology; 2009 Apr 01; 73(4):860-5; discussion 865-7. PubMed ID: 19168203
    [Abstract] [Full Text] [Related]

  • 16. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
    Martinez AA, Demanes DJ, Galalae R, Vargas C, Bertermann H, Rodriguez R, Gustafson G, Altieri G, Gonzalez J.
    Int J Radiat Oncol Biol Phys; 2005 Aug 01; 62(5):1322-31. PubMed ID: 16029788
    [Abstract] [Full Text] [Related]

  • 17. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
    Kupelian P, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A, Kuban D.
    Int J Radiat Oncol Biol Phys; 2005 Nov 01; 63(3):795-9. PubMed ID: 15925452
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.